Farrerol ameliorates hepatic insulin resistance via AMPKα1/mTOR/SREBP-1 pathway: A study in T2DM rat models and palmitic acid-induced BRL 3 A hepatocytes | Synapse
March 3, 2026
Farrerol ameliorates hepatic insulin resistance via AMPKα1/mTOR/SREBP-1 pathway: A study in T2DM rat models and palmitic acid-induced BRL 3 A hepatocytes
Key Points
Farrerol reduces hepatic insulin resistance effectively, impacting the ampkα1 pathway.
Insulin resistance improved by 30% in T2DM rat models after farrerol treatment over four weeks.
Assessment using palmitic acid-induced BRL 3A hepatocytes supports the pathway mechanisms.
Highlights the need for further studies to validate these findings in clinical settings.